Context: Neutropenia is one of the grave consequences of cancer chemotherapy, and the treatment of neutropenic febrile patients with intravenous (iv) antibiotics has been shown to reduce mortality. Oral therapy could be an alternative approach for selected patients.
Introduction
Neutropenic patients often harbour serious infections 1 -4 and therefore are traditionally treated in hospital with intravenous (iv) broad-spectrum antibiotics, at the emergence of fever. 5 Observational studies during the last decade have revealed the heterogeneous nature of febrile neutropenia. 6 Several clinical prediction rules have been developed and validated to define patients at low risk for mortality and complications. 7 -9 Oral treatment avoids the inconvenience of an iv line and its complications, is less costly than the standard treatment and therefore might be considered beneficial for low risk patients.
Clinical trials explored the feasibility of oral antibiotic treatment for low risk febrile neutropenia. 10, 11 Most of these trials were small and single centre. Thus, although reporting similar rates of success for oral and iv therapy, the superiority of an iv regimen could not be ruled out. We performed a systematic review and meta-analysis in an attempt to provide better evidence regarding the safety and efficacy of oral treatment as opposed to iv treatment.
Methods
The full protocol is available at http://www.update-software.com/
We have compared the efficacy of oral antibiotic/s versus iv antibiotic therapy in febrile neutropenic cancer patients. We also compared the efficacy of these treatment modalities in the following subgroups: patients with unexplained fever at presentation versus documented infection; absolute neutrophil count (ANC) of >0.1Â10 9 cells/L versus below; solid tumour versus haematological malignancy and children versus adults.
Eligible studies were randomized trials, comparing any oral antibiotics with any iv antibiotics for the treatment of febrile neutropenia induced by chemotherapy in cancer patients, irrespective of language and publication status.
The primary outcomes were all-cause mortality at 30 days and treatment failure. Whenever all-cause mortality could not be obtained, infectious-related mortality was used. For the purpose of this review, treatment failure was defined as a composite end-point comprising one or more of the following: death; persistence, recurrence or worsening of clinical signs or symptoms of presenting infection; any addition to or modification of the assigned intervention.
12,13 Secondary outcomes were: treatment failure other than modification of the primary intervention, lost to follow-up before end of study (dropouts). Adverse effects were defined as life-threatening or associated with permanent disability and those requiring discontinuation of therapy. ((fever*:ME OR febrile OR infection*:ME OR infect* OR sepsis*:ME) AND (neutropenia*:ME OR neutropen* OR neutropaen* OR granolucytopen* OR granolucytopaen* OR leukopen* OR leukopaen*) AND (oral OR per os) AND (intravenous OR parenteral) AND ((antibiotics*:ME OR antibiot* OR antimicrob* OR anti-microb* OR antibact* OR anti-infective agents*:ME) NOT decontamination*:ME))
Search strategy
References of all identified studies as well as major reviews were inspected to track down further studies. We searched conference proceedings and trial databases for ongoing and unpublished trials. Additionally, the first or corresponding author of each included study was contacted, as were pharmaceutical companies, for complementary information or information regarding unpublished trials.
Retrieval of studies and data
One reviewer inspected the abstract of each reference identified by the search and applied the inclusion criteria. For possibly relevant articles, the full article was obtained and inspected by two reviewers independently. They assessed the relevant articles for methodological quality and extracted data from included trials. This was conducted using the criteria described in the Cochrane handbook, which are based on the evidence of a strong association between poor allocation concealment and overestimation of effect.
14,15 Data extractions were discussed, decisions documented and all authors of included studies were contacted for clarification. In case of disagreement between the two reviewers, a third reviewer extracted the data. All data were collected on an intention-to-treat basis whenever possible.
Statistical analysis
Relative risks with 95% confidence intervals for dichotomous data were calculated. Exclusions after randomization were reported.
Heterogeneity in the results of the trials was initially graphically inspected and assessed by calculating tests of heterogeneity (x 2 and I 2 ). Heterogeneity was explored through stratifying by the above-defined patient subgroups ('objectives'), separating patients by different low risk criteria.
A fixed effect model was used unless significant heterogeneity (P<0.10) was detected, in which case the random effect model was used.
A funnel plot, estimating the precision of trials, was examined in order to estimate potential asymmetry that may indicate selection bias or methodological flaw in small studies. Publication bias was estimated also by the formal Begg-Mazumdar rank correlation test. 16 
Results

Description of studies
The process used to identify eligible trials is described in Figure 1 .
Fifteen randomized controlled trials were included in the review: 13 published studies 10,11,47 -57 and two conference proceedings, identified through ICAAC search 58, 59 (further information was provided by Dr Anaissie
59
).
The studies were performed during the years 1989-1999, and included 2511 randomized patients or episodes. Oral antibiotics were compared with intravenous, both given empirically and as the initial treatment ('initial oral') in 10 trials. In the other five trials, all patients received iv antibiotics prior to oral therapy ('sequential'). 47, 49, 52, 53, 55 In two 'sequential' trials, patients were randomized at presentation, but switched to oral therapy if clinically stable 72 h later. 47, 49 The setting of therapy also varied. All patients were treated as outpatients in four trials. 11, 52, 54, 58 In three trials, patients randomized to oral therapy were treated as outpatients, whereas the control group was treated in hospital (Table 1) . 50, 57, 59 Some exclusion criteria were common to all trials: haemodynamic instability, hypotension, altered mental status, (Table 2) . Few studies had remarkably high mortality rates with both regimens (5% -8.8%). 10, 47, 49, 51 This can be explained by the design of the trials: randomization of patients not episodes, 10,47,49 longer follow-up period, 51 and not applying most low risk criteria for inclusion. 10, 47, 49 Methodological quality of included studies Adequate allocation concealment was employed in six trials. One trial was double-blinded 48 and in another the outcomes assessors were blinded to the treatment arm. 51 Duration of follow-up was pre-defined only in two trials. 51, 53 In the other trials, it had varied according to the length of neutropenic febrile episode. In two trials, the patients were followed for a predefined time after resolution fever. In the other trials, patients were followed until the end of the febrile neutropenic episode or the end of antibiotic treatment.
The unit of randomization was the patient in four trials 10, 49, 51, 59 and the episode of febrile neutropenia in the other trials. The later trials included 1430 episodes in 1017 patients.
Efficacy of oral antibiotics
Mortality (15 trials, 2224 patients). No difference in mortality between oral and iv treatment was demonstrated (all-cause mortality: RR 0.83, 95% CI 0.49 to 1.40; Figure 2 ). Treatment failure (15 trials, 2295 patients). There was no significant difference in failure rate between the two interventions (per protocol analysis: RR 0.96, 95% CI 0.84 -1.11.
Intention-to-treat analysis: RR 0.94, 95% CI 0.84 -1.05, n = 2511, 15 trials; Figure 3) . A comparable relative risk was calculated for failure that was not due to modification of the initial regimen. Subgroup analysis. Oral treatment was not inferior when compared with iv treatment in any of the evaluated subgroups (Table 3) . Patients with ANC >0.1Â10 9 cells/L had better outcome with oral treatment. This subgroup is expected to be at a lower risk for mortality and complications, and therefore it may be that the advantages of oral treatment are more pronounced. Comparison of mortality in subgroups could not be performed due to the low fatal outcome rate. Dropouts before end of study (12 trials, 2180 patients). Twelve of the 15 included trials reported the number of patients who were lost to follow-up before the end of the study. 10,11,48 -51,53 -57,59 No significant difference in the number of dropouts was found between the oral and iv treatment (RR 0.87, 95% CI 0.65 -1.15). Adverse events. No trial reported death or permanent damage due to the study drug. Adverse effects that required discontinuation of the assigned antibiotic therapy were reported in 11 10,11,47 -50,52,55,57 trials (RR 1.79, 95% CI 0.51 -6.29; n = 1536). Separate analysis of the 'initial oral' studies revealed significantly more adverse events requiring discontinuation among orally treated patients (RR 6.65, 1.75 -25.33). This finding is explained by the high rates of gastrointestinal adverse events with oral antibiotics and with the fact that these events hamper oral but not iv treatment (post-protocol analysis: RR 3.01, 95% CI 0.99-9.12; n = 607). Resistance. Only three trials reported resistance by the microbial isolates to both antibiotic regimens. Four trials reported failure due to resistance; 49 -51,57 there was no difference between oral and iv treatment. Sensitivity analyses. Sensitivity analyses of studies with adequate and inadequate quality showed no significant impact on mortality or treatment failure. Sensitivity analyses on different case definitions showed similar relative risks: in the six trials that included patients with any source of infection, patients who were treated orally had RR 0.96, 95% CI 0.72 -1.29 for treatment failure. 10, 11, 47, 49, 54, 56 Most of the trials included patients with haematological malignancy (but not acute leukaemia). The RR for treatment failure with oral therapy in those trials was 0.9, 95% CI 0.74 -1.09. Treatment setting had no significant effect on failure. When analyses were performed according to oral antibiotic regimen, we observed no significant impact of quinolone treatment alone versus quinolones in combination with other antibiotics (Figure 4) .
A near symmetry was demonstrated on the funnel plot ( Figure 5 ). The Begg-Mazumdar test demonstrated no significant association between the study effects and size (P = 0.488).
Discussion
The rates of treatment failures and death were similar in neutropenic patients given oral and iv antibiotic treatment. Intentionto-treat analysis might favour equivalence; however, the results of the 'per-protocol' analysis were similar to those of the primary analysis. This effect was stable in a wide range of patients.
One limitation of the analysis is its inability to define the patients who may have been offered oral antibiotics. This is due to the variations in the inclusion and exclusion criteria. The difference in low risk criteria is not surprising: the concept of 'low risk' neutropenic fever and its definition developed during the years in which the studies were performed. Different prognostic criteria evolved based on observational studies. 6,7,9,60 -62 International collaboration had led to the development of a weighted scoring system identifying low risk patients, 8 adopted by IDSA. 5 Favourable factors are: the development of fever out of hospital, age below 60 years, no to moderate symptoms, no hypotension, no chronic bronchitis, no dehydration and either solid tumour or no history of fungal infection. While receiving conventional therapy this group had 1% mortality.
Low mortality rate led to wide confidence intervals in the absolute risk reduction. To confirm equivalence of two treatments, we should ideally be able to show that any estimate of risk included within the confidence interval lay within a predefined range of equivalence and had no clinical significance. 63 In a population with an expected mortality of <1%, this uncertainty may have no real consequences.
For treatment failure, the confidence interval is narrower and probably has no clinical importance since failure means mainly a change in the antibiotic regimen.
According to the available data, oral antibiotic therapy can be safely offered to febrile children and adults with neutropenia who are haemodynamically stable, have no organ failure, can take oral medications, and do not have pneumonia, infection of a central line or a severe soft-tissue infection. These criteria stand in close relationship to those used in the guidelines of IDSA for the treatment of neutropenic patients. Oral treatment may improve the quality of life of cancer patients, reduce the complication associated with iv therapy and lower the costs of the treatment.
The analysis offered no data in support of a specific oral regimen, but in light of the preponderance of Gram-positive infections, 5 ,62 the combination of a quinolone and a second drug active against Gram-positive bacteria (e.g., ampicillin/clavulanate) seems prudent. A future trial of oral versus iv antibiotic treatment should include febrile neutropenic patients with mild and stable sepsis, regardless of their underlying disorder, source of infection or neutrophil count. Its sample size should be based on considerations of equivalence. 63 The definitions of response and failure 
